These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 20358432)

  • 21. Statistical issues of QT prolongation assessment based on linear concentration modeling.
    Tsong Y; Shen M; Zhong J; Zhang J
    J Biopharm Stat; 2008; 18(3):564-84. PubMed ID: 18470764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Creation of a knowledge management system for QT analyses.
    Tornøe CW; Garnett CE; Wang Y; Florian J; Li M; Gobburu JV
    J Clin Pharmacol; 2011 Jul; 51(7):1035-42. PubMed ID: 20978278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple comparisons of repeatedly measured response: issues of validation testing in thorough QT/QTc clinical trials.
    Tsong Y; Yan LK; Zhong J; Nie L; Zhang J
    J Biopharm Stat; 2010 May; 20(3):654-64. PubMed ID: 20358443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Revisit the combination validation test of Tsong et al. for thorough QT/QTc clinical trials.
    Sun GG; Quan H
    J Biopharm Stat; 2010 May; 20(3):683-7; author reply 688. PubMed ID: 20358445
    [No Abstract]   [Full Text] [Related]  

  • 25. Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval.
    Iwamoto M; Kost JT; Mistry GC; Wenning LA; Breidinger SA; Marbury TC; Stone JA; Gottesdiener KM; Bloomfield DM; Wagner JA
    J Clin Pharmacol; 2008 Jun; 48(6):726-33. PubMed ID: 18441333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Electrocardiographic QTc changes due to moxifloxacin infusion.
    Malik M; Hnatkova K; Schmidt A; Smetana P
    J Clin Pharmacol; 2009 Jun; 49(6):674-83. PubMed ID: 19451404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of manual and automated measurements of the QT interval in healthy volunteers: an analysis of five thorough QT studies.
    Fosser C; Duczynski G; Agin M; Wicker P; Darpo B
    Clin Pharmacol Ther; 2009 Nov; 86(5):503-6. PubMed ID: 19339965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple comparisons of repeated measured response: issues of assessment of prolongation of QT interval in thorough QT trials.
    Tsong Y; Zhong J
    J Biopharm Stat; 2010 May; 20(3):604-14. PubMed ID: 20358439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Baseline correction in parallel thorough QT studies.
    Zhang J; Dang Q; Malik M
    Drug Saf; 2013 Jun; 36(6):441-53. PubMed ID: 23620166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of the average baseline versus the time-matched baseline in parallel group thorough QT/QTc studies.
    Meng Z; Quan H; Fan L; Kringle R; Sun G
    J Biopharm Stat; 2010 May; 20(3):665-82. PubMed ID: 20358444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of vardenafil and sildenafil on cardiac repolarization.
    Morganroth J; Ilson BE; Shaddinger BC; Dabiri GA; Patel BR; Boyle DA; Sethuraman VS; Montague TH
    Am J Cardiol; 2004 Jun; 93(11):1378-83, A6. PubMed ID: 15165918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sample size calculation for thorough QT/QTc study considering various factors related to multiple time points.
    Meng Z; Kringle R; Chen X; Zhao PL
    J Biopharm Stat; 2010 May; 20(3):563-77. PubMed ID: 20358436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of the sensitivity of detecting drug-induced QTc changes using subject-specific rate correction.
    Cassani González R; Engels EB; Dubé B; Nadeau R; Vinet A; LeBlanc AR; Sturmer M; Becker G; Kus T; Jacquemet V
    J Electrocardiol; 2012; 45(6):541-5. PubMed ID: 22960165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome.
    Chen X; Cass JD; Bradley JA; Dahm CM; Sun Z; Kadyszewski E; Engwall MJ; Zhou J
    Br J Pharmacol; 2005 Nov; 146(6):792-9. PubMed ID: 16158069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thorough QT study with recommended and supratherapeutic doses of tolterodine.
    Malhotra BK; Glue P; Sweeney K; Anziano R; Mancuso J; Wicker P
    Clin Pharmacol Ther; 2007 Mar; 81(3):377-85. PubMed ID: 17339867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects.
    Démolis JL; Kubitza D; Tennezé L; Funck-Brentano C
    Clin Pharmacol Ther; 2000 Dec; 68(6):658-66. PubMed ID: 11180026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study.
    Malik M; van Gelderen EM; Lee JH; Kowalski DL; Yen M; Goldwater R; Mujais SK; Schaddelee MP; de Koning P; Kaibara A; Moy SS; Keirns JJ
    Clin Pharmacol Ther; 2012 Dec; 92(6):696-706. PubMed ID: 23149929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exposure-response modeling approach for assessing QT effect in "thorough" QT/QTc studies.
    Hosmane B; Locke C; Chiu YL
    J Biopharm Stat; 2010 May; 20(3):615-31. PubMed ID: 20358440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Absence of QTc prolongation with betrixaban: a randomized, double-blind, placebo- and positive-controlled thorough ECG study.
    Morganroth J; Gretler DD; Hollenbach SJ; Lambing JL; Sinha U
    Expert Opin Pharmacother; 2013 Jan; 14(1):5-13. PubMed ID: 23216423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of intravenous zanamivir on cardiac repolarization.
    Lou Y; Gan J; Peppercorn A; Gould E; Weller S; Piscitelli SC; Patel P
    Pharmacotherapy; 2013 Jul; 33(7):701-9. PubMed ID: 23553534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.